MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$42,286,000
EPS
-$0.59
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenues from licensing and sales of intellectual property
-
-
0
0
Research and development
35,163,000
28,716,000
29,488,000
22,950,000
Zentera in-process research and development
-
-
0*
-
General and administrative
9,228,000
9,139,000
7,905,000
10,784,000
Non-cash items
-
-
0*
-
Accruals
-
-
1,612,000*
-
Non-cash items
-
-
-1,612,000*
-
Restructuring
0
0
0
0
Goodwill impairment
-
-
0*
-
Total operating expenses
44,391,000
37,855,000
37,393,000
33,734,000
Loss from operations
-44,391,000
-37,855,000
-37,393,000
-33,734,000
Investment and other income, net
2,243,000
2,623,000
2,619,000
7,043,000
Net loss before income taxes
-42,148,000
-35,232,000
-34,774,000
-26,691,000
Income tax expense
138,000
120,000
442,000*
0
Loss on equity method investment
-
-
0*
-
Net loss
-
-
-35,216,000
-26,691,000
Net loss attributable to noncontrolling interests
-
-
0
0
Net loss
-42,286,000
-35,352,000
-35,216,000
-26,691,000
Basic EPS
-0.59
-0.5
-0.491
-0.37
Diluted EPS
-0.59
-0.5
-0.491
-0.37
Basic Average Shares
71,326,000
70,264,000
71,667,000
72,139,000
Diluted Average Shares
71,326,000
70,264,000
71,667,000
72,139,000
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$42,286,000
(-57.35%↓ Y/Y)
Net loss before
income taxes
-$42,148,000
(-56.84%↓ Y/Y)
Income tax expense
$138,000
Investment and other
income, net
$2,243,000
(-75.58%↓ Y/Y)
Loss from operations
-$44,391,000
(-23.11%↓ Y/Y)
Total operating
expenses
$44,391,000
(23.11%↑ Y/Y)
Research and development
$35,163,000
(27.36%↑ Y/Y)
General and
administrative
$9,228,000
(9.23%↑ Y/Y)
Buy us a coffee
Zentalis Pharmaceuticals, Inc. (ZNTL)
Zentalis Pharmaceuticals, Inc. (ZNTL)